Verastem (VSTM) had its "buy" rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.
Verastem (VSTM) had its "buy" rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)